By Billy Candra 
A pioneering, federally funded clinical trial has unveiled a transformative approach to breast cancer care, demonstrating the feasibility of identifying survivors at elevated risk of recurrence due to dormant cancer cells and effectively neutralizing these "sleeper cells" using existing, repurposed medications. This significant research, spearheaded by scientists from the Abramson Cancer Center at the University of Pennsylvania and Penn’s Perelman School of Medicine, was formally published today in the prestigious journal Nature Medicine, marking a potential paradigm shift in post-treatment surveillance and intervention strategies for breast cancer.
The Persistent Challenge of Breast Cancer Recurrence
Despite remarkable advancements in early detection and therapeutic modalities, which have significantly improved breast cancer survival rates over the past few decades, the specter of recurrence remains a formidable challenge. For the approximately 30 percent of breast cancer survivors—both women and men—who experience a relapse, the disease often becomes incurable, necessitating continuous, indefinite treatment that manages but cannot eradicate the cancer completely. The timing of recurrence can vary dramatically, with aggressive subtypes like triple-negative breast cancer (TNBC) and HER2-positive breast cancer often returning within a few years, while hormone receptor-positive (ER+) breast cancers can unpredictably resurface decades after initial treatment. This prolonged uncertainty imposes immense psychological and emotional burdens on survivors, compounded by the lack of tools to proactively identify and target the underlying cause of relapse: dormant tumor cells. Until this breakthrough, clinicians lacked a reliable, real-time method to pinpoint individuals harboring these latent cells and to intervene with a preventive treatment to avert an otherwise incurable metastatic relapse.
Globally, breast cancer remains the most common cancer among women, with an estimated 2.3 million new cases diagnosed each year. In the United States alone, over 280,000 new cases of invasive breast cancer are projected annually. While the five-year survival rate for localized breast cancer is exceptionally high (around 99%), this figure drops dramatically to 31% for metastatic breast cancer, underscoring the critical need for strategies to prevent progression to advanced stages. The economic burden of breast cancer, encompassing treatment costs, lost productivity, and long-term care, runs into billions of dollars annually, making any intervention that can prevent recurrence not only a medical but also a significant public health and economic triumph.
A Novel Strategy: Targeting Minimal Residual Disease (MRD)
The core of this groundbreaking study revolves around the concept of minimal residual disease (MRD), often referred to as "sleeper cells" or dormant tumor cells. These are cancer cells that survive initial treatments and lie quiescent within the body, primarily in sites like bone marrow, without actively proliferating. Because they are metabolically inactive or slow-cycling, they evade conventional chemotherapy and radiation, which primarily target rapidly dividing cells. Furthermore, their dormant state means they do not form detectable tumors on standard imaging scans (such as mammograms, CT scans, or PET scans) used to monitor for recurrence. This stealthy nature allows them to persist for years, even decades, before reactivating and initiating metastatic spread, at which point the disease is typically incurable.
The current study builds upon foundational research led by Lewis Chodosh, MD, PhD, Chair of Cancer Biology and senior author of the publication. Dr. Chodosh’s earlier work meticulously unraveled the specific cellular pathways that enable these dormant tumor cells to survive undetected in patients for extended periods. "Our research illuminates a critical window of opportunity—this sleeper phase—where we can intervene to eradicate dormant tumor cells before they have the chance to re-emerge as aggressive, metastatic disease," explained Dr. Chodosh. He further emphasized a crucial discovery: "Surprisingly, we’ve found that certain drugs which are ineffective against actively growing cancers can be remarkably effective against these sleeper cells. This fundamentally indicates that the biology of dormant tumor cells is distinctly different from their active, proliferating counterparts, opening new avenues for targeted therapies."
Preclinical Foundations and Drug Repurposing
The journey to this clinical breakthrough began in the laboratory with rigorous preclinical studies. Dr. Chodosh’s team conducted a series of sophisticated experiments in mouse models to meticulously understand the underlying mechanisms governing cancer cell dormancy. Their investigations identified key cellular pathways, specifically autophagy and mTOR signaling, as critical for the survival of dormant tumor cells. Autophagy is a cellular process involving the degradation and recycling of cellular components, essential for cell survival under stress, while mTOR signaling regulates cell growth, proliferation, and survival. Disrupting these pathways could theoretically awaken or eliminate the dormant cells.
Based on these findings, the researchers identified two existing drugs, already approved by the U.S. Food and Drug Administration (FDA) for treating other conditions, that could effectively target these pathways. The strategic repurposing of existing drugs offers significant advantages, including a known safety profile, established manufacturing processes, and potentially faster translation from bench to bedside compared to developing entirely new compounds. In their preclinical models, these repurposed drugs successfully cleared minimal residual disease in mice, leading to significantly prolonged survival without cancer recurrence. This robust preclinical validation provided the necessary impetus to translate their findings into human clinical trials.
The CLEVER Clinical Trial: A Landmark Phase II Study
The clinical translation of this scientific understanding culminated in the randomized Phase II CLEVER clinical trial. Led by principal investigator Angela DeMichele, MD, MSCE, FASCO, the Mariann T. and Robert J. MacDonald Professor in Breast Cancer Research, the trial enrolled 51 breast cancer survivors who had completed their primary treatment within the previous five years and had no evidence of active disease on standard imaging scans.
The trial initiated with a crucial screening phase: participants underwent bone marrow biopsies to detect the presence of dormant tumor cells. This innovative screening step is itself a significant advancement, as it provides a direct, albeit invasive, method for identifying individuals truly at risk. If dormant tumor cells were detected in their bone marrow, patients became eligible for enrollment in the therapeutic arm of the CLEVER trial.
Participants were then randomized into three groups: monotherapy with one of the two study drugs, or combination therapy with both drugs. Patients received six cycles of the assigned treatment. The results were compelling: the treatment successfully cleared dormant tumor cells from an impressive 80 percent of the study participants. After a median follow-up period of 42 months (3.5 years), the outcomes were even more striking. The three-year survival rate without any disease recurrence was above 90 percent in patients who received monotherapy with one of the drugs, and a remarkable 100 percent for patients who received the combination of both study drugs. Only two patients across the entire study experienced a cancer recurrence during the follow-up period.
"The lingering fear of cancer returning is a profound burden that weighs heavily on many breast cancer survivors long after they complete treatment," stated Dr. DeMichele. "Currently, our capabilities are limited to a ‘wait and see’ approach, leaving both patients and clinicians without real answers about future risk. Our study unequivocally demonstrates that preventing recurrence by actively monitoring for and targeting dormant tumor cells is a strategy that holds immense promise. I am hopeful that these results will catalyze a surge in further research in this critically important area."
Broader Implications and Future Directions
This study represents a significant step towards a proactive, personalized approach to breast cancer after initial therapy. By identifying and eliminating dormant cells, it offers the potential to move beyond the current reactive model, where intervention only begins once recurrence is established and often incurable.
Key Implications:
- Paradigm Shift in Surveillance: The ability to identify high-risk individuals via MRD detection could transform post-treatment surveillance, leading to more targeted and effective preventive strategies.
- Reduced Patient Anxiety: Providing a concrete intervention against the threat of recurrence could substantially alleviate the psychological distress and "fear of the unknown" experienced by survivors.
- Cost-Effective Intervention: The repurposing of existing, FDA-approved drugs could make this preventive strategy more accessible and affordable compared to the development and approval of entirely new compounds. The cost-effectiveness of preventing incurable metastatic disease far outweighs the investment in early intervention.
- Broader Applicability: The principles of identifying and targeting dormant cancer cells may extend beyond breast cancer to other malignancies known for late recurrences, such as prostate cancer, melanoma, and certain leukemias.
- Understanding Cancer Biology: The finding that dormant cells respond differently to drugs than active cells offers new insights into cancer biology and potential drug resistance mechanisms.
While the results of the CLEVER trial are highly encouraging, researchers are proceeding with caution and rigor. As a Phase II trial, its primary aim was to assess safety and preliminary efficacy in a relatively small cohort. To confirm and expand upon these findings, Dr. DeMichele’s team is already actively enrolling patients in two larger, ongoing Phase II clinical trials: the ABBY clinical trial and the PALAVY clinical trial. These studies are being conducted at multiple cancer centers across the country, aiming to validate the results in larger and more diverse patient populations, further investigate optimal dosing and duration, and explore potential biomarkers for response.
A Collaborative Effort
This landmark research was made possible through substantial funding from critical governmental and philanthropic organizations. Key financial support was provided by the National Cancer Institute (R01CA208273) and the Department of Defense (BC160784), underscoring the national importance placed on addressing cancer recurrence. Additional vital support was contributed by the V Foundation, the Breast Cancer Research Foundation, QVC "Shoes on Sale," the Avon Foundation, the Raynier Institute & Foundation, and numerous generous philanthropic donations. Dr. DeMichele previously presented interim outcomes data from the CLEVER study at the European Society for Medical Oncology (ESMO) Congress 2023, generating significant international interest.
The collaborative spirit, spanning basic science to clinical application and supported by a diverse funding coalition, exemplifies the multidisciplinary effort required to tackle complex challenges like cancer recurrence. This new approach offers a beacon of hope for countless breast cancer survivors, suggesting a future where the lingering fear of relapse can be proactively addressed, paving the way for truly definitive long-term remission. Patients interested in learning more about these or other breast cancer clinical trials at Penn Medicine are encouraged to contact [email protected]
